Skip to content

Zymeworks ZYME Accounts payable and other current liabilities

Accounts payable and other current liabilities at other companies

AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-$9.41M-176%

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.79B+125%

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's accounts payable and other current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's accounts payable and other current liabilities?
Zymeworks (ZYME) reported accounts payable and other current liabilities of -$7.75M in Q1 2026.
How has Zymeworks's accounts payable and other current liabilities changed year-over-year?
Zymeworks's accounts payable and other current liabilities increased by 63.5% year-over-year, from -$21.22M to -$7.75M.
What does accounts payable and other current liabilities mean?
Tracks the net change in short-term obligations owed to suppliers and service providers. An increase represents a source of cash through extended payment terms, while a decrease indicates the settlement of outstanding liabilities.